🔗 Share this article

While America proceeds with historic revisions to its vaccine recommendations, one figure has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning COVID-19 vaccines during the pandemic and has concentrated on potential deaths following Covid vaccination in her recent tenure at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Health officials planned to unveil sweeping changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of step with many the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this calendar year.

A New Direction at the FDA

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting certain childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a nation with universal health coverage and a population approximately the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

The appointee has little discernible experience in medication creation, oversight or management, which has been typical for previous heads of the biologics center. She has been employed at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, said Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Former heads of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she lacks the type of experience that previous people who ran CBER have had.”

CDER has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the innovative therapies, but the off-patent medication office clears numerous generic medications. There is also a biosimilars program, over-the-counter program and so forth, and each of these must be managed,” Dr. Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the job, which oversees more than 5,000 employees. “It’s a huge administrative position, if you execute it properly,” she added.

Agency Reaction and Contentious Policies

In response to inquiries about Dr. Høeg's credentials and whether this selection indicates more teamwork among agency officials on vaccines, a representative responded that the “concerns rely on incorrect presumptions”.

“Her resume is consistent with the functions of her job,” the representative stated, citing the time Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's new priority voucher program, a controversial one-day drug-approval program that allegedly troubled her predecessors. “By what process are these medications being picked for this fast-track system? Who makes the decisions?” Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards more relaxed oversight of most medications, except for immunizations.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, past, critics said. She authored a analysis using non-validated volunteer-provided data to determine the rate of heart inflammation following Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the incoming government encompassed revising rules for novel immunizations and discontinuing “non-essential” immunizations, she said post-election on a podcast. At the FDA, Høeg has according to sources proposed preventing adolescent males from receiving Covid vaccines.

“She’s an complete dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the science in a extremely misleading, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|